@WHO: The new deals are in addition to existing agreements with: -the Serum Institute of India for 200M doses – with options for up to 900M doses more of either the AstraZeneca/Oxford or Novavax candidates -the Sanofi/GSK for 200M doses #COVID19 https://t.co/woYn4Tyj1k

http://twitter.com/WHO
via IFTTT